the product in the database has an inactive status
indications:
Arterial hypertension. Symptomatic treatment of benign prostatic hyperplasia.
Composition:
1 tabl sustained release contains 4 mg Doxazosin as mesilate.
Action:
A selective and competitive antagonist of postsynaptic α receptors1adrenergic. Doxazosin reduces blood pressure by reducing peripheral vascular resistance. After a single daily dose, a clinically significant reduction in blood pressure persists for 24 hours. It reduces triglycerides and total cholesterol and increases the ratio of HDL to total cholesterol in the blood, causes regression of left ventricular hypertrophy, inhibits platelet aggregation and increases the activity of tissue plasminogen activator. patients with impaired insulin sensitivity increases the sensitivity of tissues to insulin. In patients with benign prostatic hyperplasia, it improves the results of urodynamic tests and reduces the symptoms of dysarthria. It blocks α receptors1-adrenergic located in the smooth muscles of the body and the prostate bag and in the bladder neck. After oral administration, doxazosin is well absorbed from the gastrointestinal tract, reaching a maximum concentration in the blood after about 6-8 hours. It binds to plasma proteins in about 98%. It is metabolized in the liver to inactive metabolites. Less than 5% of the dose is excreted unchanged. T0,5 is 22 hours.
Contraindications:
Hypersensitivity to Doxazosin, other quinazoline derivatives or other ingredients of the preparation. Benign prostatic hyperplasia coexisting with congestion of the upper urinary tract, chronic urinary tract infections or urinary calculi. Bladder overflow, anuria or progressive renal failure. Gastrointestinal obstruction or esophagus or narrowing of the gastrointestinal tract. Breastfeeding period. The preparation should not be used in patients under 18 years of age.
Precautions:
Particularly cautiously use in the treatment of benign prostatic hyperplasia in patients with hypotension or in patients with orthostatic dysregulation. Use with caution in patients with pulmonary edema following aortic or mitral valve stenosis; heart failure with a large minute capacity; right ventricular failure following pulmonary embolism or pericardial effusion and left ventricular failure with low heart inflation pressure. In hypertensive patients with additional risk factors for cardiovascular disease, doxazosin should not be used as the sole treatment for hypertension (risk of developing heart failure). Use with caution in patients with diabetic autonomic neuropathy and those with mild to moderate hepatic impairment. Due to the lack of tests, the preparation is not recommended in severe hepatic impairment.
Pregnancy and lactation:
It must not be used during pregnancy unless clearly necessary. The use of the preparation is contraindicated during breast-feeding.
Side effects:
Common: apathy, muscle spasms, weakness, headache, drowsiness, accommodation disturbances, palpitations, chest pain, dizziness, edema, orthostatic symptoms, shortness of breath, rhinitis, constipation, dyspepsia, frequent urge to urinate, pollakiuria, delayed ejaculation, asthenia. Uncommon: increased thirst, hypokalemia, gout, nightmares, amnesia, emotional instability, muscle tremor or stiffness, tearing, photophobia, tinnitus, arrhythmia, angina pectoris, bradycardia or tachycardia, myocardial infarction, hypotension, syncope, peripheral ischemia, nosebleed, bronchospasm, cough, pharyngitis, lack of appetite or increased appetite, dysgeusia, alopecia, edema, muscle pain and weakness, swelling and pain in the joints, urinary disorders (including urinary incontinence), flushing, fever , chills, paleness.Rare: hypoglycaemia, depression, agitation, paresthesias, visual disturbances, cerebrovascular disorders, laryngeal edema, dyspepsia, diarrhea, vomiting, jaundice, rash, pruritus, purpura, impotence, priapism, increased liver enzymes, decreased body temperature in patients with old age. Very rare: increased urea and creatinine in the blood.
Dosage:
Orally. Adults: usually 4 mg once a day; if necessary, the dose may be increased up to a maximum dose of 8 mg once a day. In the treatment of hypertension, the product may be used as monotherapy or combination therapy (eg with a thiazide diuretic, β-adrenergic antagonist, Calcium antagonist or ACE inhibitor). No dosage adjustment is necessary in patients with impaired renal function or in elderly patients. The tablets should be swallowed whole, with or without water, with water.
(C)
